EA032705B1 - Способ лечения или предупреждения энтеропатии - Google Patents

Способ лечения или предупреждения энтеропатии Download PDF

Info

Publication number
EA032705B1
EA032705B1 EA201591899A EA201591899A EA032705B1 EA 032705 B1 EA032705 B1 EA 032705B1 EA 201591899 A EA201591899 A EA 201591899A EA 201591899 A EA201591899 A EA 201591899A EA 032705 B1 EA032705 B1 EA 032705B1
Authority
EA
Eurasian Patent Office
Prior art keywords
rifaximin
nsaid
bid
diclofenac
administration
Prior art date
Application number
EA201591899A
Other languages
English (en)
Russian (ru)
Other versions
EA201591899A1 (ru
Inventor
Джузеппе Клаудио Вискоми
Мария Гримальди
Мария Виттория Фольи
Паола Маффей
Чечилиа Ренцулли
Аннализа Сфорцини
Коррадо Бландицци
Кармело Скарпиньято
Original Assignee
Альфасигма С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альфасигма С.П.А. filed Critical Альфасигма С.П.А.
Publication of EA201591899A1 publication Critical patent/EA201591899A1/ru
Publication of EA032705B1 publication Critical patent/EA032705B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201591899A 2013-04-12 2014-04-11 Способ лечения или предупреждения энтеропатии EA032705B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811619P 2013-04-12 2013-04-12
US201361845240P 2013-07-11 2013-07-11
PCT/IB2014/060640 WO2014167533A1 (en) 2013-04-12 2014-04-11 Nsaid administration and related compositions, methods and systems.

Publications (2)

Publication Number Publication Date
EA201591899A1 EA201591899A1 (ru) 2016-03-31
EA032705B1 true EA032705B1 (ru) 2019-07-31

Family

ID=50687535

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591899A EA032705B1 (ru) 2013-04-12 2014-04-11 Способ лечения или предупреждения энтеропатии

Country Status (14)

Country Link
US (2) US20140308350A1 (enExample)
EP (1) EP2983647B1 (enExample)
JP (1) JP6433980B2 (enExample)
KR (1) KR102190173B1 (enExample)
CN (1) CN105324109A (enExample)
AU (1) AU2014252219B2 (enExample)
CA (1) CA2908525C (enExample)
EA (1) EA032705B1 (enExample)
ES (1) ES2829285T3 (enExample)
MX (1) MX374340B (enExample)
NZ (1) NZ713440A (enExample)
PL (1) PL2983647T3 (enExample)
PT (1) PT2983647T (enExample)
WO (1) WO2014167533A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
CN107550908A (zh) * 2016-06-30 2018-01-09 康普药业股份有限公司 一种治疗下肠道溃疡的药物组合物
US20190336511A1 (en) * 2018-05-02 2019-11-07 Georgiy Brusovanik Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094737A2 (en) * 2005-03-07 2006-09-14 Alfa Wassermann S.P.A. Gastroresistant pharmaceutical formulations containing rifaximin
WO2009108814A1 (en) * 2008-02-26 2009-09-03 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
WO2012038898A1 (en) * 2010-09-22 2012-03-29 Alfa Wassermann S.P.A. Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2011153444A1 (en) 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
AU2013212008A1 (en) * 2012-01-25 2014-07-10 Alfa Wassermann S.P.A. Rifaximin derivative and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094737A2 (en) * 2005-03-07 2006-09-14 Alfa Wassermann S.P.A. Gastroresistant pharmaceutical formulations containing rifaximin
WO2009108814A1 (en) * 2008-02-26 2009-09-03 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
WO2012038898A1 (en) * 2010-09-22 2012-03-29 Alfa Wassermann S.P.A. Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENONI, G.; CUZZOLIN, L.; RAIMONDI, M. G.; VELO, G. P.: "Indomethacin - induced intestinal lesions and fecal flora", ADVANCES IN INFLAMMATION RESEARCH, vol. 6, 1 January 1984 (1984-01-01), pages 103 - 108, XP009178493 *
CARLA J. GARGALLO, ANGEL LANAS: "Is NSAIDs-related gastrointestinal damage preventable?", JOURNAL OF DIGESTIVE DISEASES, BLACKWELL PUB. ASIA, vol. 14, no. 2, 24 February 2013 (2013-02-24), pages 55 - 61, XP055122750, ISSN: 17512972, DOI: 10.1111/1751-2980.12019 *
L Ciobanu ET AL.: "European Review for Medical and Pharmacological Sciences 344 Effects of rifaximin on indomethacin-induced intestinal damage in guinea-pigs", 1 February 2014 (2014-02-01), XP055122760, Retrieved from the Internet:URL:http://www.europeanreview.org/wp/wp-content/uploads/344-351.pdf [retrieved on 2014-06-11], the whole document *
LANAS ANGEL; SCARPIGNATO CARMELO: "Microbial flora in NSAID-induced intestinal damage: A role for antibiotics?", DIGESTION, S. KARGER AG., BASEL, CH, vol. 73, no. Suppl. 1, CH, pages 136 - 150, XP009178466, ISSN: 0012-2823, DOI: 10.1159/000089789 *
SCARPIGNATO C, PELOSINI I: "Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential", CHEMOTHERAPY, S. KARGER AG, CH, vol. 51, no. suppl. 1, 1 January 2005 (2005-01-01), CH, pages 36 - 66, XP009107325, ISSN: 0009-3157, DOI: 10.1159/000081990 *
ZWOLINSKA-WCISLO MALGORZATA M; KONTUREK PETER C; DROZDOWICZ DANUTA; KARCZEWSKA ELZBIETA; KWIECIEN SLAWOMIR; URBANCZYK KATARZYNA; K: "Beneficial Effects of Probiotic Saccharomyces boulardi and Rifaximine in Stress- and NSAID-Induced Exacerbation of Experimental Colitis", GASTROENTEROLOGY : OFFICIAL PUBLICATION OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION, WILLIAMS & WILKINS, US, vol. 142, no. 5, suppl. 1, 1 May 2012 (2012-05-01), US, pages s46, XP009178452, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(12)60175-9 *

Also Published As

Publication number Publication date
ES2829285T3 (es) 2021-05-31
EA201591899A1 (ru) 2016-03-31
MX2015014307A (es) 2015-12-08
WO2014167533A1 (en) 2014-10-16
JP2016520556A (ja) 2016-07-14
PT2983647T (pt) 2020-11-09
EP2983647A1 (en) 2016-02-17
NZ713440A (en) 2019-02-22
PL2983647T3 (pl) 2021-01-25
HK1213810A1 (en) 2016-07-15
KR20150140390A (ko) 2015-12-15
MX374340B (es) 2025-03-06
CN105324109A (zh) 2016-02-10
AU2014252219B2 (en) 2018-11-22
CA2908525A1 (en) 2014-10-16
CA2908525C (en) 2021-04-06
US20190388411A1 (en) 2019-12-26
EP2983647B1 (en) 2020-09-09
KR102190173B1 (ko) 2020-12-14
AU2014252219A1 (en) 2015-10-29
US20140308350A1 (en) 2014-10-16
JP6433980B2 (ja) 2018-12-05

Similar Documents

Publication Publication Date Title
BRPI0709745A2 (pt) forma de dosagem oral, e, mÉtodo para prevenir ou reduzir a severidade, duraÇço, e/ou sintomas de um distérbio gastrintestinal
JP2011512416A (ja) オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
RU2385154C2 (ru) Составы и способы подавления секреции желудочного сока
JP7493048B2 (ja) 経口投与用の医薬組成物
US20190388411A1 (en) Nsaid administration and related compositions, methods and systems
US20040131676A1 (en) Dosage forms containing a PPI, NSAID, and buffer
KR102139346B1 (ko) HMG-CoA 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제
AU2005204014B2 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
WO2004062552A2 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
JP7566164B2 (ja) テゴプラザンおよび非ステロイド性抗炎症薬を含有する医薬組成物
US20040082514A1 (en) Methods for treatment of helicobacter pylori-associated disorders
US20110020439A1 (en) Delayed release compositions of duloxetine
JP2004035535A (ja) 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法
HK1213810B (en) Nsaid administration and related compositions, methods and systems
US11696894B2 (en) Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor
CN1524517B (zh) 含非甾体消炎药的口服药物组合物及其制备方法
BR112015018952B1 (pt) Composições farmacêuticas contendo dexcetoprofeno e tramadol, seu método de fabricação e seu uso
BR112021003563A2 (pt) composição farmacêutica, método para prevenir ou tratar doenças relacionadas à trombogênese e uso de clopidogrel ou sais
EA046600B1 (ru) Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты
BR102017003179A2 (pt) forma de dosagem unitária, composição farmacêutica e processo para sua preparação
BR102017003179B1 (pt) Forma de dosagem unitária, processo para preparação de uma forma de dosagem unitária e composição farmacêutica sólida oral
TH94263A (th) องค์ประกอบของรูปแบบยาทางเภสัชกรรมชนิดใหม่ล่าสุดที่มีการปลดปล่อยแบบดัดแปรซึ่งประกอบด้วยตัวยับยั้งเอนไซม์ไซโคลออกซีเจเนส

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM